Showing results (831-840 of 903) with videos related to

Sort By:
Pageof 91
Annals of Internal Medicine|April 12, 2021
A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is VaccinatedDean Follmann, Jonathan Fintzi, Michael P Fay, et al.
Lancet (London, England)|August 13, 2021
Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trialFirdausi Qadri, Farhana Khanam, Xinxue Liu, et al.
The Lancet. Global Health|October 22, 2021
Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trialMila Shakya, Merryn Voysey, Katherine Theiss-Nyland, et al.
Ebiomedicine|September 22, 2023
Risk of COVID-19 after natural infection or vaccinationAnne-Marie Rick, Matthew B Laurens, Ying Huang, et al.
Vaccines|April 3, 2021
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline CharacteristicsAndrea Haekyung Haselbeck, Birkneh Tilahun Tadesse, Juyeon Park, et al.
Nature Metabolism|January 17, 2025
Recommendations for mitochondria transfer and transplantation nomenclature and characterizationJonathan R Brestoff, Keshav K Singh, Katia Aquilano, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Research Square|May 13, 2022
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim AnalysisEvan Anderson, Lisa Jackson, Nadine Rouphael, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 10, 2024
COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled TrialsAmy C Sherman, Jessica Tuan, Valeria D Cantos, et al.
Pageof 91